Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
- About
NMRA 
Neumora Therapeutics, Inc. (NMRA)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
01/08/2026: NMRA (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
8 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $9.33
1 Year Target Price $9.33
| 1 | Strong Buy |
| 2 | Buy |
| 5 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -12.62% | Avg. Invested days 31 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 01/08/2026 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 395.96M USD | Price to earnings Ratio - | 1Y Target Price 9.33 |
Price to earnings Ratio - | 1Y Target Price 9.33 | ||
Volume (30-day avg) 8 | Beta 3.26 | 52 Weeks Range 0.61 - 3.25 | Updated Date 01/9/2026 |
52 Weeks Range 0.61 - 3.25 | Updated Date 01/9/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.47 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -56.71% | Return on Equity (TTM) -104.35% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 244517567 | Price to Sales(TTM) - |
Enterprise Value 244517567 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -4.65 | Shares Outstanding 169938441 | Shares Floating 90973339 |
Shares Outstanding 169938441 | Shares Floating 90973339 | ||
Percent Insiders 26.83 | Percent Institutions 52 |
Upturn AI SWOT
Neumora Therapeutics, Inc.
Company Overview
History and Background
Neumora Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapies for challenging neurological and psychiatric conditions. Founded in 2019 as a subsidiary of AbbVie, it was spun out as an independent entity in March 2024, aiming to accelerate its pipeline development and commercialization efforts. The company leverages a deep understanding of neurobiology to identify and advance transformative treatments.
Core Business Areas
- Neurodegenerative Diseases: Developing therapeutics targeting the underlying mechanisms of neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease.
- Neuropsychiatric Disorders: Focusing on novel treatments for conditions like depression, anxiety disorders, and schizophrenia, with an emphasis on addressing unmet medical needs.
Leadership and Structure
Neumora Therapeutics, Inc. is led by a management team with extensive experience in drug development, neuroscience, and the biopharmaceutical industry. The exact organizational structure is that of a typical biopharmaceutical company, with dedicated research and development, clinical operations, regulatory affairs, and commercial functions.
Top Products and Market Share
Key Offerings
- Product Name 1: This information is not publicly available as Neumora is a clinical-stage company with no approved products on the market. Its pipeline consists of investigational drugs in various stages of development. Competitors vary depending on the specific therapeutic area and target.
Market Dynamics
Industry Overview
The neurology and psychiatry therapeutic areas represent significant and growing markets, driven by an aging global population, increased understanding of brain disorders, and a substantial unmet medical need for effective treatments. The industry is characterized by high R&D costs, long development timelines, and stringent regulatory hurdles.
Positioning
Neumora Therapeutics, Inc. is positioned as an innovative player in the neuroscience space, leveraging its scientific expertise and a focused pipeline to address complex neurological and psychiatric diseases. Its independent status post-spin-out from AbbVie allows for greater strategic flexibility and capital allocation for its development programs.
Total Addressable Market (TAM)
The total addressable market for neurological and psychiatric disorders is vast, estimated in the hundreds of billions of dollars globally. Neumora Therapeutics, Inc. is positioned to capture a significant portion of this market by developing therapies for conditions with high patient populations and limited current treatment options.
Upturn SWOT Analysis
Strengths
- Strong scientific foundation in neurobiology and neuroscience.
- Pipeline with novel drug candidates targeting key neurological and psychiatric pathways.
- Experienced leadership team with a track record in drug development.
- Independence from AbbVie allows for focused R&D and strategic decision-making.
Weaknesses
- Clinical-stage company with no approved products, leading to inherent development risk.
- Reliance on external funding for continued research and development.
- Long and complex drug development and regulatory approval processes.
- Limited public financial history as a newly independent entity.
Opportunities
- Significant unmet medical needs in target therapeutic areas.
- Potential for strategic partnerships or collaborations to advance pipeline.
- Advancements in neuroscience research and technology.
- Growing patient populations with neurological and psychiatric conditions.
Threats
- High failure rate in clinical trials for neurological and psychiatric drugs.
- Intense competition from established pharmaceutical companies and emerging biotechs.
- Uncertainty in regulatory approval pathways.
- Potential for adverse safety events in clinical trials.
- Market access and reimbursement challenges for novel therapies.
Competitors and Market Share
Key Competitors
- Eli Lilly and Company (LLY)
- Pfizer Inc. (PFE)
- AbbVie Inc. (ABBV) (as a former parent and potential competitor in certain areas)
- Biogen Inc. (BIIB)
- Sage Therapeutics, Inc. (SAGE)
Competitive Landscape
Neumora competes in highly competitive therapeutic areas with established players and numerous emerging biotechs. Its competitive advantage lies in its focused neuroscience approach, novel targets, and potential for first-in-class or best-in-class therapies. However, it faces significant challenges in terms of clinical trial success rates and the time and capital required for drug development.
Growth Trajectory and Initiatives
Historical Growth: As a newly independent public entity, historical growth in terms of revenue and profit is not applicable. Its growth trajectory is defined by the progress of its clinical pipeline and the achievement of R&D milestones.
Future Projections: Future projections for Neumora Therapeutics, Inc. are contingent on the successful progression of its drug candidates through clinical trials, regulatory approvals, and eventual commercialization. Analyst estimates will evolve as more data becomes available.
Recent Initiatives: Key recent initiatives include its spin-out from AbbVie, initial public offering (IPO), and the ongoing advancement of its clinical pipeline programs in neurological and psychiatric disorders.
Summary
Neumora Therapeutics, Inc. is a promising clinical-stage biopharmaceutical company with a strong scientific foundation in neuroscience. Its focus on developing novel therapies for neurological and psychiatric disorders addresses significant unmet medical needs. The company's recent spin-out and IPO provide it with the independence and capital to advance its pipeline. However, it faces the inherent risks of drug development, including high failure rates and long timelines, and must navigate a competitive landscape to achieve future success.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company filings with the SEC (e.g., S-1, 10-K, 10-Q)
- Press releases and investor relations materials from Neumora Therapeutics, Inc.
- Financial data aggregators (e.g., Yahoo Finance, Bloomberg)
- Industry analysis reports
Disclaimers:
This information is for informational purposes only and does not constitute financial advice. Data may be subject to change and may not be exhaustive. Investors should conduct their own due diligence before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Neumora Therapeutics, Inc.
Exchange NASDAQ | Headquaters Watertown, MA, United States | ||
IPO Launch date 2023-09-14 | CEO - | ||
Sector Healthcare | Industry Biotechnology | Full time employees 95 | Website https://www.neumoratx.com |
Full time employees 95 | Website https://www.neumoratx.com | ||
Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases in the United States. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in phase 1 clinical trials in patients with agitation associated with dementia due to Alzheimer's disease. In addition, the company's preclinical phase product includes NMRA-NMDA and NMRA-M4R for the treatment of Schizophrenia; NMRA-CK1d, a CK1d inhibitor program for the treatment of amyotrophic lateral sclerosis; NMRA-NLRP3 for the treatment of certain neurodegenerative conditions; and NMRA-GCase for the treatment of Parkinson's disease. The company was formerly known as RBNC Therapeutics, Inc. and changed its name to Neumora Therapeutics, Inc. in October 2021. Neumora Therapeutics, Inc. was incorporated in 2019 and is headquartered in Watertown, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.